Company intelligence / Profile preview

Angio-Proteomie

Boston, Massachusetts, United States
Ownership
Private
Development stage
Other
01

Overview

Angio-Proteomie offers over 15,000 research products including monoclonal and polyclonal antibodies, recombinant proteins, primary human/animal cells and cell lines, and custom services for antibody and cell line development; no clinical therapeutic assets

Therapeutic areas
OncologyNeurologyCardiovascularOther
Modalities
Monoclonal antibodyPolyclonal antibodyRecombinant proteinsiRNACell therapy (primary human/animal cells, labeled cells)
Industry
Non-Drug Biotech
02

Partnerships

Distributor relationships with PELOBiotech and Probioscience Singapore

Beyond the preview

Go deeper on Angio-Proteomie.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Angio-Proteomie.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call